Stockreport

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics, Inc.  (CYTH) 
PDF Strategic merger with Rafael Holdings to combine two companies and advance Trappsol® Cyclo™ for NPC1 patients expected to close Q4 2024Company on track for topline data [Read more]